Category «alzheimers»

CT-1812

It’s only fair to share…   CT-1812 Elayta Condition(s): Alzheimer’s Disease U.S. FDA Status: Alzheimer’s Disease (Phase 2) Company: Cognition Therapeutics Inc. CAS: 1802632-22-9 Chemical Formula: C24H33NO4S Molecular Weight: 431.591 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol Phenol, 4-[3-[1,3-dihydro-5-(methylsulfonyl)-2H-isoindol-2-yl]-3-methylbutyl]-2-(1,1-dimethylethoxy)- Originator Cognition Therapeutics Class Antidementias; Neuroprotectants; Nootropics; Small molecules Mechanism of Action Sigma-2 receptor antagonists Phase II Alzheimer’s disease Phase I Cognition disorders 21 Feb 2019 Cognition Therapeutics receives patent for …